T9195 |
SHR0302
|
1445987-21-2
|
99.11%
|
|
SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 4...
|
T5382 |
Ritlecitinib
|
1792180-81-4
|
99.1%
|
|
Ritlecitinib (PF-06651600) is a potent JAK3-selective inhibitor (IC50: 33.1 nM).
|
T2709 |
TAK-901
|
934541-31-8
|
99.1%
|
|
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others....
|
TN1059 |
Ganoderic acid B
|
81907-61-1
|
99.09%
|
|
Ganoderic acid B is a chemical marker in quality control of G. lucidum and related products. Ganoderic acid B-containing herbs has potential influence towards th...
|
T2156 |
WP1066
|
857064-38-1
|
99.07%
|
|
WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3. WP1066 has ...
|
TQ0037 |
Abrocitinib
|
1622902-68-4
|
99.05%
|
|
Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).
|
T12427 |
Brepocitinib P-Tosylate
|
2140301-96-6
|
98.99%
|
|
Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).
|
T9251 |
Fedratinib hydrochloride hydrate
|
1374744-69-0
|
98.96%
|
|
Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.
|
T4657 |
WHI-P97
|
211555-05-4
|
98.91%
|
|
WHI-P97 is a rationally designed potent inhibitor of JAK-3. IC50 value: Target: JAK3 Treatment of mast cells with WHI-P97 inhibited the translocation of 5-lipoxy...
|
T13571 |
JAK-IN-10
|
916741-98-5
|
98.88%
|
|
JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.
|
T22142 |
RO8191
|
691868-88-9
|
98.85%
|
|
RO8191 (CDM-3008) (CDM-3008), an imidazonaphthyridine compound, is an agonist of interferon (IFN) receptor.
|
T3065 |
TG101209
|
936091-14-4
|
98.81%
|
|
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
|
T20742 |
TG-89
|
936091-56-4
|
98.8%
|
|
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cer...
|
T11710 |
JAK-IN-5
|
2096999-92-5
|
98.78%
|
|
JAK-IN-5 is a JAK inhibitor (Compound 283 from patent US20170121327A1).
|
T1849 |
Momelotinib
|
1056634-68-4
|
98.75%
|
|
Momelotinib (LM-1149) is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with IC50 of 11 nM/18 nM. JAK1/2 inhibitor CYT387 comp...
|
T3080 |
Pyridone 6
|
457081-03-7
|
98.7%
|
|
Pyridone 6 (JAK Inhibitor)(CMP 6) is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM); ...
|
T2853 |
Curcumol
|
4871-97-0
|
98.57%
|
|
Curcumol ((-)-Curcumol), a pure monomer isolated extracted from Rhizoma Curcumaeis, has antitumor activities.
|
T4657L |
WHI-P97 HCl 211555-05-4(free base)
|
T4657L
|
98.55%
|
|
WHI-P97 HCl is a potent and selective JAK-3 inhibitor. WHI-P97 had an estimated Ki value of 0.09 microM from modeling studies and a measured IC50 value of 2.5 mi...
|
T14687 |
Deucravacitinib
|
1609392-27-9
|
98.52%
|
|
Deucravacitinib (BMS-986165) inhibits IL-12/23 and type I IFN pathways[1][2]. BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for...
|
T3398 |
Icaritin
|
118525-40-9
|
98.50%
|
|
Icaritin (Anhydroicaritin) has hormone regulation activity and cardiovascular function improvement activity. Icaritin has anticancer activity, can induce S phase...
|